Biotech Values

[rfj1862]

ALT’s weight-loss efficacy data are no better than what patients are already achieving with approved GLP-1 drugs such as NVO’s Wegovy and LLY’s Mounjaro, and its safety/tolerability data may be worse. Hence, the Pemvidutide program looks like it won’t be competitive unless the phase-3 data are considerably better than the (interim) phase-2 data, which is pretty unlikely.

VKTX took a big sympathy hit because of this. Results from a Phase 1 study of their similar drug are expected in the next 2 weeks.

Obviously a silly overreaction since VKTX is in phase 1 on that program, hasn't released data, and the whole thing is really just a sideshow to the NASH phase 2b results coming in 1H 2023